Proton therapy in the management of non-Hodgkin lymphoma. Issue 9 (2nd September 2015)

• Record Type: Journal Article
• Authors: Sachsman, Suzanne; Flampouri, Stella; Li, Zuofeng; Lynch, James; Mendenhall, Nancy P.; Hoppe, Bradford S.
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 9(2015:Sep.)
• Page Start: 2608
• Page End: 2612
• Publication Date: 2015-09-02
• Subjects: Lymphoma and Hodgkin disease -- radiation -- outcomes -- proton beam therapy; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2015.1014364
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract : Proton therapy (PT) is a highly conformal type of radiation therapy that can target the tumor while sparing dose to surrounding normal tissues. This study reviews a single institution's experience managing patients with non-Hodgkin lymphoma (NHL) treated with PT. Eleven patients with NHL were treated with PT from January 2008 to January 2014 on an institutional review board-approved outcomes tracking protocol, and included patients with indolent orbital lymphoma ( n = 4), primary mediastinal B-cell lymphoma ( n = 3), plasmablastic lymphoma ( n = 2) and natural killer (NK) T-cell lymphoma ( n = 2). The median follow-up was 38 months. The 2-year rate of local control was 91%, with one patient with NK T-cell lymphoma having recurrence in-field. Toxicities were limited to grade 2 at highest, during follow-up. PT is a feasible and effective treatment for NHL. Early outcomes are favorable. Longer follow-up and more patients are needed to confirm our findings.